THE COMPARISON BETWEEN DEFICIT FUNCTIONAL NEUROLOGIST WITH VON WILLEBRAND FACTOR LEVELS IN ACUTE THROMBOTIC STROKE PATIENTS

Ita Muharram Sari, Mohammad Saiful Islam
  MNJ, pp. 1-8  

Abstract


Background. There are limited studies of von Willebrand factor (vWF) and thrombotic stroke, escpecially the relationship between level of vWF and functional neurological deficit.
Objective. To determine the difference between functional neurological deficit; measured by the NIHSS scale with the vWF level.
Methods. Design study was cross sectional, sampling by consecutive admission according to inclusion and exclusion criteria. Blood samples were taken for vWF measurement. Patients are divided into two categories, low vWF level and high vWF levels. Deficit functional neurologist was measured by NIHSS scale.
Results. The results were analyzed by chi square. From 80 patients, the result compares the level of NIHSS scale. In grup with mild NIHSS and low vWF levels (50 %) higher than grup with mild NIHSS and high vWF levels (27,27 %). In other side, grup with moderate NIHSS and low vWF levels (50 %) lower than grup with moderate NIHSS and high vWF levels (72,73 %). The difference is not significant statistically (p=0.067).
Conclusion. There was no difference between deficit functional neurologist measured by NIHSS scale with von Willebrand factor levels in acute thrombotic stroke patients.


Keywords


level of vWF; NIHSS; stroke trombotik

Full Text:

PDF

References


Nichols M, Townsend N, Scarborough P, Rayner M. European Cardiovascular Disease Statistics, Brussel: European Heart Network and European Society of Cardiology. 2012. pp1-129.

Jauch EC, Saver JL, Adams HP, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the Early Management of Patients with Acute Ischemic Stroke, A Guideline for Healthcare Professionals From the American Heart Association/ American Stroke Association. Stroke 2013.p44.

Balitbangkes Depkes RI, 2008. Riset Kesehatan Dasar (Riskesdas) 2007. Jakarta: Depkes RI. 2008. hlm. 276-285.

Spiel AO, Gilbert JC, Jilma B. Von Willebrand Factor in Cardiovascular Disease: Focus on Acute Coronary Syndromes. Circulation 2008;117:1449-1459.

Hanson E, Jood K, Karlsson S, Nilsson S, Blomstrand C, Jern C. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost 2011; 9:275-81.

De Meyer SF, Deckmyn H, Vanhoorelbeke K. Von Willebrand factor to the rescue. Blood 2009; 113: 5049-5057.

De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C. Von Willebrand Factor An Emerging Target in Stroke Therapy. Stroke 2012; 43: 599-606.

Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JCM, de Maat MPM, et al. High von Willebrand Factor Kadars Increase the Risk of Stroke: The Rotterdam Study. Stroke 2010; 41: 2151- 2156.

Saenger AK, Christenson RH. Stroke Biomarkers: Progress and Challenges for Diagnosis, Prognosis, Differentiation, and Treatment. Clinical Chemistry 2010; 56(1): 2133.

Beer C, Blacker D, Hankey GJ, Puddey IB. Association of clinical and aetiologic subtype of acute ischaemic stroke with inflammation, oxidative stress and vascular function: A crosssectional observational study. Med Sci Monit 2011; 17(9): CR467-473.

Conway DSG, Pearce LA, Chin BSP, Hart RG, Lip GYH. Prognostic Value of Plasma von Willebrand Factor and Soluble P-Selectin as Indices of Endothelial Damage and Platelet Activation in 994 Patients with Nonvalvular Atrial Fibrillation. Circulation 2003; 107: 31413145.

Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and target for treatment. Blood 2008; 112: 3555-3562.

Lapchak PA, Doyan S, Fan X, Woods CM. Synergistic Effect of AJW200, a von Willebrand Factor Neutralizing Antibody with Low Dose (0,9 mg.mg) Thrombolytic Therapy Following Embolic Stroke in Rabbits. J Neurol Neurophysiol 2013; 4(2):1-5.

Hubbard AR, Hamill M, Beeharry M, Bevan S, Heath AB. Expert Committee On Biological Standardization: Value Assignment of the Proposed 6th International Standard for Blood Coagulation Factor VII and von Willebrand Factor in Plasma, Human. Geneva: WHO Press. 2009. hlm. 1-41.

Adams HP, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A Report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999; 53(1): 126-131.

Farrokhi F, Smiley D, Umpierrez GE. Glycemic Control in Non Diabetic Critically Ill Patients. Elsevier USA 2011; 25:813-24.

Ueshima H, Choudhury SR, Okayama A, Hayakama T, Kita Y, Kadowaki T, et al. Cigarette Smoking as a Risk Factor for Stroke Death in Japan. Stroke 2004; 35:1836-1841.

Malyszko J, Muntner P, Rysz J, Banach M. Blood Pressure Levels and Stroke: J-curve Phenomenon?. Curr Hypertens Rep 2013; 15: 575-581.

Caplan LR. Stroke Prevention. Dalam: Caplan LR, editor. Caplan’s Stroke A Clinical Approach. Edisi ke-4. Philadelphia: Elsevier Saunders; 2009. hlm. 582-87.

Bushnell CD. Stroke in Women. Dalam: Goldstein LB, editor. A Primer on Stroke Prevention Treatment: An Overview Based on AHA/ASA Guidelines. West Sussex: WileyBlackwell; 2009. hlm. 115-118.

Qureshi AI, Ezzedine MA, Nasar A, Suri MF, Kirmani JF, Hussein HM, et al. Prevalence of Elevated Blood Pressure in 563704 Adult Patients Presenting to Emergency Department with Stroke in the United States. Am J Emerg Med 2007; 25: 32-38.

Leonardi-Bee J, Bath PMW, Phillips SJ, Sandercock PAG. Blood Pressure and Clinical Outcomes in the International Stroke Trial. Stroke 2002; 33: 1315-1320.

William LS, Rotich J, Qi R, Fineberg N, Espay A, Bruno A, dkk. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 59: 67-71.

Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in diabetic and non diabetic: A Systematic Review. Stroke 2001; 32: 2426-2432.

Rojnuckarin P, Akkawat B, Intragumtornchai T. Von Willebrand Factor (vWF) Antigen Kadars and Function in Healthy Thais. Southeast Asian J Trop Med Public Health 2005; 36(5): 12921297.

Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 1994; 88: 601-607.

Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, et al. Von Willebrand factor, C-Reactive Protein, and 5-year mortality in diabetic and non diabetic subjects: The Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19: 3071-8

Von Beckerath N, Koch W, Mehilli J, Gorchakova O, Braun S, Schomig A,et al. ABO locus O1 allele and risk of myocardial infarction. Blood Coagul Fibrinolysis 15: 61-67.

Van Loon JE, Leebeek FWG, Deckers JW, Dippel DWJ, Poldermans D, Strachan DP, et al. Effect of Genetic Variations in Syntaxin Binding Protein-5 and Syntaxin-2 on von Willebrand Factor concentration and cardiovascular risk. Circ Cardiovask Genet. 2010; 3(6): 507-12.

Van Schie MC, De Maat MPM, Isaacs A, van Duijn CM, Deckers JW, Dippel DW, et al. Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease. Blood 2011;117(4): 1393-1399.

Sukhu K, Poovalingam V, Mahomed R, Giangrande PL. Ethnic variation in von Willebrand factor levels can influence the diagnosis of von Willebrand disease. Clin Lab Haematol 2003; 25(4); 247-249.

Ruggeri ZM. Old concepts and new developments in the study of platelet aggregation. J Clin Invest 2000; 105: 699-701.

Chauhan AK, Kisucka J, Lamb CB, Bergmeier W, Wagner DD. Von Willebrand Factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood 2006; 109: 2424-2429.

Jackson SP. The Growing Complexity of Platelet Aggregation. Blood 2007; 109; 5087-5095

Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000;106: 385-392.

Maurer LM, Tomasini-Johansson BR, Mosher DF.Emerging Role of fibronectin in thrombosis. Thromb Res 2010; 125(4): 287-291.

Hynes RO. The dynamic dialogue between cells and matrices: Implications of fibronectin’s elasticity. Proc Nati Acad Sci USA 1996; 96: 2588-2590.

Olorundare OE, Peyruchaud O, Albrecht RM, Mosher DF. Assembly of a fibronectin matrix by adherent platelets stimulated by lysophosphatidic acid and other agonists. Blood 2001; 98: 117-124.

De Mast Q, Groot E, Asih PB, Syafruddin D, Oosting M, Sebastian S, et al. ADAMTS13 Deficiency with Elevated Levels of Ultra- Large and Active von Willebrand Factor in P. Falciparum and P. Vivax Malaria. Am. J. Trop. Med. Hyg 2009; 80(3): 492-498.

Keightley AM, Lam YM, Brady JN, Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: Identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood 1999; 93: 4277-4283.

Harvey PJ, Keightley AM, Lam YM, Cameron C, Lillicrap D. A single nucleotide polymorphism at nucleotide -1793 in the von Willebrand factor(vWF) regulatory region is associated with plasma vWF: Ag levels. Br J Haematol 2000; 109: 349-353.

Bongers TN, de Maat MPM, van Goor MPJ, Bhagwanbali V, van Vliet HHDM, Garcia EBG, et al. High von Willebrand Factor Kadars Increase the Risk of First Ischemic Stroke Influence of ADAMTS 13, Inflammation and Genetic Variability. Stroke 2006; 37: 2672-2677.

Van Loon JE, Kavous M, Leebeek FWG, Felix JF, Hofman A, Witteman JCM, et al.von Willebrand Factor plasma levels, genetic variations, and coronary heart disease in an older population. J Thromb Haemost 2012; 10(7): 1262-9.

Simon D, Palatnik M, Roisenberg I. Analysis of the-1185A/G von Willebrand factor (vWF) gene polymorphism in two Brazilian ethnic groups and its effect on the plasma vWF levels. Thromb Res. 2002; 105: 519-522.


Refbacks

  • There are currently no refbacks.